Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 438 of 1,261
  1. US 10575537

    Saury Maillard peptide and its preparation method and application

    South China University of Technology · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  2. US 10576107

    Methods of treating joint diseases, disorders, and conditions with tissue inhibitors of matrix metalloproteinases

    Prime Merger Sub, LLC · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  3. US 10577607

    Modulation of DYRK1B expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  4. US 10577605

    Induced exon inclusion in spinal muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  5. US 10577410

    Compositions and methods for treating and preventing Staphylococcus aureus infections

    XBIOTECH INC. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  6. US 10577382

    Fused heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  7. US 10577406

    FKBP-L polypeptides and uses in angiogenesis-mediated disorders

    ALMAC DISCOVERY LIMITED · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  8. US 10577349

    Quinolinones as inhibitors of translation initiation complex

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  9. US 10577368

    A3 adenosine receptor agonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  10. US 10577361

    Dopamine D3 receptor antagonists having a morpholine moiety

    Indivior UK Limited · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  11. US 10577347

    Crystalline forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  12. US 10577344

    Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins

    The Board of Regents of the University of Texas System · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  13. US 10576095

    Use of aminoglycoside analogs in the treatment of Rett syndrome

    ELOXX PHARMACEUTICALS LTD. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  14. US 10576099

    Injectable scaffold for treatment of intracranial aneurysms and related technology

    Covidien LP · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  15. US 10576059

    Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV

    The United States of America, as Represented by the Secretary, Department of Human Services · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  16. US 10576091

    Tomatidine, analogs thereof, compositions comprising same, and uses for same

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  17. US 10577604

    Methods for monitoring C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  18. US 10576096

    Tumor-selective combination therapy

    The Board of Regents of the University of Texas System · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  19. US 10577381

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  20. US 10577631

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  21. US 10575521

    Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds

    INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  22. US 10576079

    Multi-drug therapies for tuberculosis treatment

    The Regents of the University of California · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  23. US 10578608

    Tools to detect, track and target cancer cells in vivo

    The Regents of the University of California · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  24. US 10576145

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.